guest ::
| Home > Publications database > Radiobiological and Treatment Planning Evidence Supporting Particle Therapy in Aggressive Breast Cancer. |
| Home > Publications database > Radiobiological and Treatment Planning Evidence Supporting Particle Therapy in Aggressive Breast Cancer. |
| Journal Article | DKFZ-2026-02051 |
; ; ; ; ; ; ; ; ; ; ; ; ; ;
2026
Elsevier Science
Amsterdam [u.a.]
Abstract: Breast cancer (BC) remains the most commonly diagnosed malignancy among women worldwide with an overall 5-year-survival rate of ∼90%. The prognosis worsens dramatically for patients with metastatic and/or aggressive subtypes. In such cases, particle therapy emerges as a promising approach, offering superior tumor control while limiting the risk of secondary pathologies.The radiobiological effects of X-rays were compared with those of protons (p), 4He and 12C ions, delivered using therapeutically-realistic Spread-Out Bragg Peaks, on 2D- and 3D-models of MDA-MB-231 (Triple-Negative (TN)) and MCF7 (ER-positive) BC cells, whereas 16O ions were used on the MDA-MB-231 cells. To achieve relevant insights, we evaluated conventional clonogenic survival and spheroid growth dynamics, mimicking tumor architecture, on both cell lines. Cell migration and invasion, tumor‑supernatant-induced angiogenesis and the expression of pro‑angiogenic factors were systematically investigated in the TN-BC subtype to assess the potential therapeutic advantages of ion-irradiation in aggressive BC models. The here-obtained in vitro data served as input for a comparative treatment planning study with p, 4He and 12C ions on ten TN-BC cases.All ions exhibited superior efficacy compared to X-ray and effectively counteracted the X-ray-induced increase in migration and invasion. 4He ions indicated a unique balance of advantages, showing greater relative biological effectiveness and inhibition of spheroid growth than p, and a reduction in migration and invasion comparable to 12C ions. In the planning and NTCP study for TN-BC (α/β=9.4Gy), with similar OAR objectives (α/β=3Gy), p and 4He ions achieved comparable CTV coverage and OARs sparing, whereas 12C exhibited reduced coverage mainly due to this large α/β difference.These findings suggest particle therapy as a promising strategy for aggressive BC, with p and 4He ions demonstrating particular potential. Importantly, 4He ions emerge as a distinctive intermediate option between protons and heavier ions, combining physical precision, biological efficacy, and clinical applicability.
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; Nationallizenz
; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |